COST EFFECTIVENESS OF ZOLEDRONIC ACID IN THE PREVENTION OF SKELETAL RELATED EVENTS IN RENAL CELL CARCINOMA PATIENTS WITH BONE METASTASES: AN EXPLORATORY ANALYSIS FOR FRANCE

被引：0
|
作者：
Botteman, M. [1 ]
Stephens, J.
Foley, I.
Kaura, S. [2 ]
机构：
[1] Pharmerit N Amer LLC, Hlth Econ, Bethesda, MD USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：201 / 202
页数：2
相关论文
共 50 条
  • [41] Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
    Lipton, A.
    Fizazi, K.
    Stopeck, A. T.
    Henry, D. H.
    Smith, M. R.
    Shore, N.
    Martin, M.
    Vadhan-Raj, S.
    Brown, J. E.
    Richardson, G. E.
    Saad, F.
    Yardley, D. A.
    Zhou, K.
    Balakumaran, A.
    Braun, A.
    EUROPEAN JOURNAL OF CANCER, 2016, 53 : 75 - 83
  • [42] Symptomatic skeletal events (SSEs) versus skeletal- related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid
    von Moos, R.
    Costa, L. A. M.
    Scagliotti, G.
    Sleeboom, H.
    Goldwasser, F.
    Hirsh, V.
    Spencer, A.
    Radcliffe, H-S.
    Niepel, D.
    Henry, D. H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO SOLID TUMOURS: AN INTEGRATED ANALYSIS OF THREE PHASE 3 STUDIES
    Stopeck, A. T.
    Richardson, G.
    Siena, S.
    Lipton, A.
    Brown, J.
    Fizazi, K.
    Henry, D.
    Saad, F.
    Ke, C.
    Braun, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S8 - S8
  • [44] RETROSPECTIVE DATABASE ANALYSIS OF THE EFFECT OF ZOLEDRONIC ACID ON SKELETAL-RELATED EVENTS IN MEN WITH PROSTATE CANCER AND BONE METASTASES
    Henk, H. J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A254 - A254
  • [45] Burden of bone metastases from renal cell carcinoma: zoledronic acid and functional Independence
    Drudge-Coates, L.
    Thompson, P. M.
    Muir, G. H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 433 - 433
  • [46] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases
    不详
    BREAST, 2005, 14 : S45 - S46
  • [47] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases
    Rosen, L.
    Gordon, D.
    Chen, Y. M.
    CANCER TREATMENT REVIEWS, 2006, 32 : S43 - S43
  • [48] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases
    不详
    BREAST, 2005, 14 : S44 - S44
  • [49] Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom
    Joshi, Avani D.
    Carter, John A.
    Botteman, Marc F.
    Kaura, Satyin
    CLINICAL THERAPEUTICS, 2011, 33 (03) : 291 - 304
  • [50] Zoledronic acid for the prevention of bone metastases in patients with breast cancer
    Coleman, R.
    Gralow, J.
    Bell, R.
    Lipton, A.
    EJC SUPPLEMENTS, 2004, 2 (03): : 74 - 75
12345